News + Font Resize -

US Court rules in favour of Impax Laboratories in Wellbutrin SR patent case
Philadelphia | Saturday, January 31, 2004, 08:00 Hrs  [IST]

GlaxoSmithKline announced that the US Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour of Impax Laboratories Inc, and upheld a lower court ruling that Impax's generic product did not infringe GSK's US patent for its antidepressant Wellbutrin SR.

GSK continues to be committed to Wellbutrin XL - its once daily version of Wellbutrin launched last fall -- which now represents nearly 40 per cent of new prescriptions being written for Wellbutrin (XL & SR).

Post Your Comment

 

Enquiry Form